However, there are potential advantages to utilizing SGLT2 inhibitors in the adjuvant treatment of T1DM, such as better blood sugar control, decreased insulin dosage, weight management and loss, lower blood pressure, and improved blood sugar fluctuation (34). This evidence concerns the gene INS and type 1 diabetes mellitus.